Bank of America Downgrades Sage Therapeutics (NASDAQ:SAGE) to Underperform
Bank of America lowered shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) from a neutral rating to an underperform rating in a research note issued to investors on Wednesday, Marketbeat Ratings reports. They currently have $14.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $24.00. A number of other […]
More Stories
Jon Bon Jovi Admits Cheating on His Wife; Reveals Sleeping With 100 Women
The recent interview of Jon Bon Jovi with The Independent has stirred up a fresh controversy. The interaction which included...
Todd A. Foley Sells 6,616 Shares of The Kroger Co. (NYSE:KR) Stock
The Kroger Co. (NYSE:KR – Get Free Report) CFO Todd A. Foley sold 6,616 shares of the stock in a...
GrafTech International Ltd. (NYSE:EAF) Major Shareholder Buys $265,332.92 in Stock
GrafTech International Ltd. (NYSE:EAF – Get Free Report) major shareholder Colonial House Capital Ltd purchased 179,279 shares of the firm’s...
Samuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a...
What Risk Factors Investors Should Note in Franklin Resources, Inc. (BEN) Quarterly Report
BEN has shown consistent revenue growth from sponsored funds, with fluctuating operating expenses. Management focuses on consolidating subsidiaries and managing...
Unpack ON Semiconductor Corp. (ON) Latest Quarterly SEC 10-Q Filing
ON has focused on providing intelligent power and sensing solutions for automotive and industrial markets to enable electrification, efficiency, and...